Exact Mass: 417.2541898
Exact Mass Matches: 417.2541898
Found 500 metabolites which its exact mass value is equals to given mass value 417.2541898,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Paspalicine
Cilazapril
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Cilazapril
Cilazapril is only found in individuals that have used or taken this drug. It is one of the angiotensin-converting enzyme inhibitors (ACE inhibitors) used for hypertension. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. [PubChem]Cilazapri, as a pyridazine ACE inhibitor, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II levels results in a decrease in blood pressure, an increase in renin activity, and stimulation of baroreceptor reflex mechanisms. Kininase II, an enzyme which degrades the vasodilator bradykinin, is identical to ACE and may also be inhibited. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
4-Hydroxytetradecanedioylcarnitine
4-Hydroxytetradecanedioylcarnitine is an acylcarnitine. More specifically, it is an 4-hydroxytetradecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hydroxytetradecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 4-Hydroxytetradecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
6-Hydroxytetradecanedioylcarnitine
6-Hydroxytetradecanedioylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxytetradecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Hydroxytetradecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 6-Hydroxytetradecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
7-Hydroxytetradecanedioylcarnitine
7-Hydroxytetradecanedioylcarnitine is an acylcarnitine. More specifically, it is an 7-hydroxytetradecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Hydroxytetradecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-Hydroxytetradecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
5-Hydroxytetradecanedioylcarnitine
5-Hydroxytetradecanedioylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxytetradecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxytetradecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-Hydroxytetradecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-hydroxytetradecanedioylcarnitine
3-hydroxytetradecanedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxytetradecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxytetradecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-hydroxytetradecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Eicosapentaenoyl Aspartic acid
C24H35NO5 (417.25151000000005)
N-eicosapentaenoyl aspartic acid belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Aspartic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Aspartic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Aspartic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Cinepazide
Decoquinate
C24H35NO5 (417.25151000000005)
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic
(Z)-4-(1-{4-[2-(Dimethylamino)ethoxy]phenyl}-5-hydroxy-2-phenylpent-1-enyl)phenol
DECOQUINATE
C24H35NO5 (417.25151000000005)
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic CONFIDENCE standard compound; INTERNAL_ID 1087
5,6-dihydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-2H,5H,6H,7H,8H,13H,13aH,14H,15H,16H,16bH-oxacyclododeca[3,2-e]isoindole-2,16-dione
C24H35NO5 (417.25151000000005)
1H-Cycloundec[d]isoindole-1,12,15-trione, 2,3,3a,4,6a,9,10,11,13,14-decahydro-11,13-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-, (7E)-
C24H35NO5 (417.25151000000005)
hydroxydaphgraciline|methyl (4S,6R,6?S,10aR,11S)-6?-ethyl-2,3,4,5,5?,6,6?,7,8,10-decahydro-6-hydroxy-6?-methoxy-2-methyl-1H,4?H-spiro[4,10a-methanopentaleno[1,6-cd]azonine-11,3?-pyran]-9-carboxylate
C24H35NO5 (417.25151000000005)
(3R,8S,Z)-3-hydroxyheptadeca-1,9-dien-4,6-diyn-8-yl 11-(1H-indol-3-yl)acetate
victoxinine-alpha-glycerophosphate
C20H36NO6P (417.22801260000006)
Ile Ala Ser Lys
C18H35N5O6 (417.25872100000004)
Ala Glu Lys Ala
Thr Val Ala Lys
C18H35N5O6 (417.25872100000004)
3-hydroxy-2-[[3-(3-hydroxy-6-methylheptanoyl)oxy-8-methylnonanoyl]amino]propanoic acid
C24H35NO5_(1aS,2R,3R,6E,10S,10aR,11S,13aS,14aS)-2,3-Dihydroxy-11-isobutyl-6,9,10-trimethyl-3,4,5,7a,10,10a,11,12-octahydro-1aH-oxireno[9,10]cycloundeca[1,2-d]isoindole-13,14(2H,14aH)-dione
C24H35NO5 (417.25151000000005)
3-hydroxy-2-[[3-(3-hydroxy-6-methylheptanoyl)oxy-8-methylnonanoyl]amino]propanoic acid [IIN-based on: CCMSLIB00000848029]
3-hydroxy-2-[[3-(3-hydroxy-6-methylheptanoyl)oxy-8-methylnonanoyl]amino]propanoic acid [IIN-based: Match]
5,6-dihydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-2H,5H,6H,7H,8H,13H,13aH,14H,15H,16H,16bH-oxacyclododeca[3,2-e]isoindole-2,16-dione_major
C24H35NO5 (417.25151000000005)
Ala Ala Glu Lys
Ala Ala Lys Glu
Ala Ala Arg Thr
Ala Ala Thr Arg
Ala Glu Ala Lys
Ala Ile Lys Ser
C18H35N5O6 (417.25872100000004)
Ala Ile Asn Thr
Ala Ile Gln Ser
Ala Ile Ser Lys
C18H35N5O6 (417.25872100000004)
Ala Ile Ser Gln
Ala Ile Thr Asn
Ala Lys Ala Glu
Ala Lys Glu Ala
Ala Lys Ile Ser
C18H35N5O6 (417.25872100000004)
Ala Lys Leu Ser
C18H35N5O6 (417.25872100000004)
Ala Lys Ser Ile
C18H35N5O6 (417.25872100000004)
Ala Lys Ser Leu
C18H35N5O6 (417.25872100000004)
Ala Lys Thr Val
C18H35N5O6 (417.25872100000004)
Ala Lys Val Thr
C18H35N5O6 (417.25872100000004)
Ala Leu Lys Ser
C18H35N5O6 (417.25872100000004)
Ala Leu Asn Thr
Ala Leu Gln Ser
Ala Leu Ser Lys
C18H35N5O6 (417.25872100000004)
Ala Leu Ser Gln
Ala Leu Thr Asn
Ala Asn Ile Thr
Ala Asn Leu Thr
Ala Asn Thr Ile
Ala Asn Thr Leu
Ala Gln Ile Ser
Ala Gln Leu Ser
Ala Gln Ser Ile
Ala Gln Ser Leu
Ala Gln Thr Val
Ala Gln Val Thr
Ala Arg Ala Thr
Ala Arg Thr Ala
Ala Ser Ile Lys
C18H35N5O6 (417.25872100000004)
Ala Ser Ile Gln
Ala Ser Lys Ile
C18H35N5O6 (417.25872100000004)
Ala Ser Lys Leu
C18H35N5O6 (417.25872100000004)
Ala Ser Leu Lys
C18H35N5O6 (417.25872100000004)
Ala Ser Leu Gln
Ala Ser Gln Ile
Ala Ser Gln Leu
Ala Thr Ala Arg
Ala Thr Ile Asn
Ala Thr Lys Val
C18H35N5O6 (417.25872100000004)
Ala Thr Leu Asn
Ala Thr Asn Ile
Ala Thr Asn Leu
Ala Thr Gln Val
Ala Thr Arg Ala
Ala Thr Val Lys
C18H35N5O6 (417.25872100000004)
Ala Thr Val Gln
Ala Val Lys Thr
C18H35N5O6 (417.25872100000004)
Ala Val Gln Thr
Ala Val Thr Lys
C18H35N5O6 (417.25872100000004)
Ala Val Thr Gln
Asp Gly Lys Val
Asp Gly Val Lys
Asp Lys Gly Val
Asp Lys Val Gly
Asp Val Gly Lys
Asp Val Lys Gly
Glu Ala Ala Lys
Glu Ala Lys Ala
Glu Lys Ala Ala
Gly Asp Lys Val
Gly Asp Val Lys
Gly Ile Lys Thr
C18H35N5O6 (417.25872100000004)
Gly Ile Gln Thr
Gly Ile Thr Lys
C18H35N5O6 (417.25872100000004)
Gly Ile Thr Gln
Gly Lys Asp Val
Gly Lys Ile Thr
C18H35N5O6 (417.25872100000004)
Gly Lys Leu Thr
C18H35N5O6 (417.25872100000004)
Gly Lys Thr Ile
C18H35N5O6 (417.25872100000004)
Gly Lys Thr Leu
C18H35N5O6 (417.25872100000004)
Gly Lys Val Asp
Gly Leu Lys Thr
C18H35N5O6 (417.25872100000004)
Gly Leu Gln Thr
Gly Leu Thr Lys
C18H35N5O6 (417.25872100000004)
Gly Leu Thr Gln
Gly Gln Ile Thr
Gly Gln Leu Thr
Gly Gln Thr Ile
Gly Gln Thr Leu
Gly Arg Ser Val
Gly Arg Val Ser
Gly Ser Arg Val
Gly Ser Val Arg
Gly Thr Ile Lys
C18H35N5O6 (417.25872100000004)
Gly Thr Ile Gln
Gly Thr Lys Ile
C18H35N5O6 (417.25872100000004)
Gly Thr Lys Leu
C18H35N5O6 (417.25872100000004)
Gly Thr Leu Lys
C18H35N5O6 (417.25872100000004)
Gly Thr Leu Gln
Gly Thr Gln Ile
Gly Thr Gln Leu
Gly Val Asp Lys
Gly Val Lys Asp
Gly Val Arg Ser
Gly Val Ser Arg
Ile Ala Lys Ser
C18H35N5O6 (417.25872100000004)
Ile Ala Asn Thr
Ile Ala Gln Ser
Ile Ala Ser Gln
Ile Ala Thr Asn
Ile Gly Lys Thr
C18H35N5O6 (417.25872100000004)
Ile Gly Gln Thr
Ile Gly Thr Lys
C18H35N5O6 (417.25872100000004)
Ile Gly Thr Gln
Ile Lys Ala Ser
C18H35N5O6 (417.25872100000004)
Ile Lys Gly Thr
C18H35N5O6 (417.25872100000004)
Ile Lys Ser Ala
C18H35N5O6 (417.25872100000004)
Ile Lys Thr Gly
C18H35N5O6 (417.25872100000004)
Ile Asn Ala Thr
Ile Asn Thr Ala
Ile Gln Ala Ser
Ile Gln Gly Thr
Ile Gln Ser Ala
Ile Gln Thr Gly
Ile Ser Ala Lys
C18H35N5O6 (417.25872100000004)
Ile Ser Ala Gln
Ile Ser Lys Ala
C18H35N5O6 (417.25872100000004)
Ile Ser Gln Ala
Ile Thr Ala Asn
Ile Thr Gly Lys
C18H35N5O6 (417.25872100000004)
Ile Thr Gly Gln
Ile Thr Lys Gly
C18H35N5O6 (417.25872100000004)
Ile Thr Asn Ala
Ile Thr Gln Gly
Lys Ala Ala Glu
Lys Ala Glu Ala
Lys Ala Ile Ser
C18H35N5O6 (417.25872100000004)
Lys Ala Leu Ser
C18H35N5O6 (417.25872100000004)
Lys Ala Ser Ile
C18H35N5O6 (417.25872100000004)
Lys Ala Ser Leu
C18H35N5O6 (417.25872100000004)
Lys Ala Thr Val
C18H35N5O6 (417.25872100000004)
Lys Ala Val Thr
C18H35N5O6 (417.25872100000004)
Lys Asp Gly Val
Lys Asp Val Gly
Lys Glu Ala Ala
Lys Gly Asp Val
Lys Gly Ile Thr
C18H35N5O6 (417.25872100000004)
Lys Gly Leu Thr
C18H35N5O6 (417.25872100000004)
Lys Gly Thr Ile
C18H35N5O6 (417.25872100000004)
Lys Gly Thr Leu
C18H35N5O6 (417.25872100000004)
Lys Gly Val Asp
Lys Ile Ala Ser
C18H35N5O6 (417.25872100000004)
Lys Ile Gly Thr
C18H35N5O6 (417.25872100000004)
Lys Ile Ser Ala
C18H35N5O6 (417.25872100000004)
Lys Ile Thr Gly
C18H35N5O6 (417.25872100000004)
Lys Leu Ala Ser
C18H35N5O6 (417.25872100000004)
Lys Leu Gly Thr
C18H35N5O6 (417.25872100000004)
Lys Leu Ser Ala
C18H35N5O6 (417.25872100000004)
Lys Leu Thr Gly
C18H35N5O6 (417.25872100000004)
Lys Pro Ser Ser
Lys Ser Ala Ile
C18H35N5O6 (417.25872100000004)
Lys Ser Ala Leu
C18H35N5O6 (417.25872100000004)
Lys Ser Ile Ala
C18H35N5O6 (417.25872100000004)
Lys Ser Leu Ala
C18H35N5O6 (417.25872100000004)
Lys Ser Pro Ser
Lys Ser Ser Pro
Lys Thr Ala Val
C18H35N5O6 (417.25872100000004)
Lys Thr Gly Ile
C18H35N5O6 (417.25872100000004)
Lys Thr Gly Leu
C18H35N5O6 (417.25872100000004)
Lys Thr Ile Gly
C18H35N5O6 (417.25872100000004)
Lys Thr Leu Gly
C18H35N5O6 (417.25872100000004)
Lys Thr Val Ala
C18H35N5O6 (417.25872100000004)
Lys Val Ala Thr
C18H35N5O6 (417.25872100000004)
Lys Val Asp Gly
Lys Val Gly Asp
Lys Val Thr Ala
C18H35N5O6 (417.25872100000004)
Leu Ala Lys Ser
C18H35N5O6 (417.25872100000004)
Leu Ala Asn Thr
Leu Ala Gln Ser
Leu Ala Ser Lys
C18H35N5O6 (417.25872100000004)
Leu Ala Ser Gln
Leu Ala Thr Asn
Leu Gly Lys Thr
C18H35N5O6 (417.25872100000004)
Leu Gly Gln Thr
Leu Gly Thr Lys
C18H35N5O6 (417.25872100000004)
Leu Gly Thr Gln
Leu Lys Ala Ser
C18H35N5O6 (417.25872100000004)
Leu Lys Gly Thr
C18H35N5O6 (417.25872100000004)
Leu Lys Ser Ala
C18H35N5O6 (417.25872100000004)
Leu Lys Thr Gly
C18H35N5O6 (417.25872100000004)
Leu Asn Ala Thr
Leu Asn Thr Ala
Leu Gln Ala Ser
Leu Gln Gly Thr
Leu Gln Ser Ala
Leu Gln Thr Gly
Leu Ser Ala Lys
C18H35N5O6 (417.25872100000004)
Leu Ser Ala Gln
Leu Ser Lys Ala
C18H35N5O6 (417.25872100000004)
Leu Ser Gln Ala
Leu Thr Ala Asn
Leu Thr Gly Lys
C18H35N5O6 (417.25872100000004)
Leu Thr Gly Gln
Leu Thr Lys Gly
C18H35N5O6 (417.25872100000004)
Leu Thr Asn Ala
Leu Thr Gln Gly
Asn Ala Ile Thr
Asn Ala Leu Thr
Asn Ala Thr Ile
Asn Ala Thr Leu
Asn Ile Ala Thr
Asn Ile Thr Ala
Asn Leu Ala Thr
Asn Leu Thr Ala
Asn Ser Val Val
Asn Thr Ala Ile
Asn Thr Ala Leu
Asn Thr Ile Ala
Asn Thr Leu Ala
Asn Val Ser Val
Asn Val Val Ser
Pro Lys Ser Ser
Pro Ser Lys Ser
Pro Ser Ser Lys
Gln Ala Ile Ser
Gln Ala Leu Ser
Gln Ala Ser Ile
Gln Ala Ser Leu
Gln Ala Thr Val
Gln Ala Val Thr
Gln Gly Ile Thr
Gln Gly Leu Thr
Gln Gly Thr Ile
Gln Gly Thr Leu
Arg Ala Ala Thr
Arg Ala Thr Ala
Arg Gly Ser Val
Arg Gly Val Ser
Arg Ser Gly Val
Arg Ser Val Gly
Arg Thr Ala Ala
Arg Val Gly Ser
Arg Val Ser Gly
Ser Ala Ile Lys
C18H35N5O6 (417.25872100000004)
Ser Ala Lys Ile
C18H35N5O6 (417.25872100000004)
Ser Ala Lys Leu
C18H35N5O6 (417.25872100000004)
Ser Ala Leu Lys
C18H35N5O6 (417.25872100000004)
Ser Gly Arg Val
Ser Gly Val Arg
Ser Ile Ala Lys
C18H35N5O6 (417.25872100000004)
Ser Ile Lys Ala
C18H35N5O6 (417.25872100000004)
Ser Lys Ala Ile
C18H35N5O6 (417.25872100000004)
Ser Lys Ala Leu
C18H35N5O6 (417.25872100000004)
Ser Lys Ile Ala
C18H35N5O6 (417.25872100000004)
Ser Lys Leu Ala
C18H35N5O6 (417.25872100000004)
Ser Leu Ala Lys
C18H35N5O6 (417.25872100000004)
Ser Leu Lys Ala
C18H35N5O6 (417.25872100000004)
Ser Arg Gly Val
Ser Arg Val Gly
Ser Val Gly Arg
Ser Val Arg Gly
Thr Ala Ala Arg
Thr Ala Lys Val
C18H35N5O6 (417.25872100000004)
Thr Ala Arg Ala
Thr Ala Val Lys
C18H35N5O6 (417.25872100000004)
Thr Gly Ile Lys
C18H35N5O6 (417.25872100000004)
Thr Gly Lys Ile
C18H35N5O6 (417.25872100000004)
Thr Gly Lys Leu
C18H35N5O6 (417.25872100000004)
Thr Gly Leu Lys
C18H35N5O6 (417.25872100000004)
Thr Ile Gly Lys
C18H35N5O6 (417.25872100000004)
Thr Ile Lys Gly
C18H35N5O6 (417.25872100000004)
Thr Lys Ala Val
C18H35N5O6 (417.25872100000004)
Thr Lys Gly Ile
C18H35N5O6 (417.25872100000004)
Thr Lys Gly Leu
C18H35N5O6 (417.25872100000004)
Thr Lys Ile Gly
C18H35N5O6 (417.25872100000004)
Thr Lys Leu Gly
C18H35N5O6 (417.25872100000004)
Thr Lys Val Ala
C18H35N5O6 (417.25872100000004)
Thr Leu Gly Lys
C18H35N5O6 (417.25872100000004)
Thr Leu Lys Gly
C18H35N5O6 (417.25872100000004)
Thr Arg Ala Ala
Thr Val Lys Ala
C18H35N5O6 (417.25872100000004)
Val Ala Lys Thr
C18H35N5O6 (417.25872100000004)
Val Ala Thr Lys
C18H35N5O6 (417.25872100000004)
Val Gly Arg Ser
Val Gly Ser Arg
Val Lys Ala Thr
C18H35N5O6 (417.25872100000004)
Val Lys Thr Ala
C18H35N5O6 (417.25872100000004)
Val Arg Gly Ser
Val Arg Ser Gly
Val Ser Gly Arg
Val Ser Arg Gly
Val Thr Ala Lys
C18H35N5O6 (417.25872100000004)
Val Thr Lys Ala
C18H35N5O6 (417.25872100000004)
16-phenoxy Prostaglandin F2a ethyl amide
C24H35NO5 (417.25151000000005)
(3E,9E)-5,6-dihydroxy-14-isobutyl-9,12,13-trimethyl-6,7,8,10a,13,13a,14,15-octahydro-2H-[1]oxacyclododecino[2,3-d]isoindole-2,16(5H)-dione
C24H35NO5 (417.25151000000005)
N-Cyclohexyl-4-[3-phenyl-5-(1-piperidinylmethyl)-1,2-oxazol-4-yl] -2-pyrimidinamine
(R)-8-FLUORO-N-ISOPROPYL-4-(3-METHOXYPROPOXY)-6-METHYL-N-(PIPERIDIN-3-YL)QUINOLINE-2-CARBOXAMIDE
C23H32FN3O3 (417.24275739999996)
4-(4-tert-Butoxycarbonylamino-cyclohexyl)-piperazine-1-carboxylic acid benzyl ester
C23H35N3O4 (417.26274300000006)
Cinepazide
C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
bis(2-hydroxyethyl)[2-hydroxy-3-(octyloxy)propyl]methylammonium methyl sulphate
(R)-α,α-Bis(3,5-dimethylphenyl)-2-pyrrolidineMethanol triMethylsilyl ether hydrochloride 97
C24H36ClNOSi (417.22545560000003)
N,N-Dimethyl-2-[[(1R,2R,4R)-1,7,7-trimethyl-2-phenylbicyclo[2.2.1]hept-2-yl]oxy]ethanamine (2E)-2-butenedioate
C20H31NO.C4H4O4 (417.25151000000005)
(Z)-4-(1-{4-[2-(Dimethylamino)ethoxy]phenyl}-5-hydroxy-2-phenylpent-1-enyl)phenol
2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)-
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists
(R)-2-((9-Isopropyl-6-((3-(pyridin-2-yl)phenyl)amino)-9H-purin-2-yl)amino)butan-1-ol
3,3-Dipentyloxacarbocyanine
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D004396 - Coloring Agents > D005456 - Fluorescent Dyes D004396 - Coloring Agents > D002232 - Carbocyanines
(9E)-4,6-Dihydroxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-9,12-diene-2,5,18-trione
C24H35NO5 (417.25151000000005)
6-Ethyl-5-[(2s)-1-(3-Methoxypropyl)-2-Phenyl-1,2,3,4-Tetrahydroquinolin-7-Yl]pyrimidine-2,4-Diamine
6-Hydroxy-10,14,15-trimethyl-17-(2-methylpropyl)-2-oxa-18-azatricyclo[10.7.0.01,16]nonadeca-10,13-diene-3,7,19-trione
C24H35NO5 (417.25151000000005)
8-Acetoxyheterophyllisine
C24H35NO5 (417.25151000000005)
A diterpene alkaloid isolated from the roots of Delphinium denudatum that exhibits antifungal activity.
1-[4-[2-Hydroxy-3-[2-phenylethyl-(phenylmethyl)amino]propoxy]phenyl]-1-propanone
(4R)-2-[4-(3-hydroxypropoxy)phenyl]-N-[2-(4-morpholinyl)ethyl]-4-prop-2-enyl-5H-oxazole-4-carboxamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclohexanecarboxamide
C23H35N3O4 (417.26274300000006)
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
N-[(4R,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(4R,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C23H35N3O4 (417.26274300000006)
2-[(1R,3R,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-(2-piperidin-1-ylethyl)acetamide
C23H35N3O4 (417.26274300000006)
2-[(1R,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-(2-piperidin-1-ylethyl)acetamide
C23H35N3O4 (417.26274300000006)
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclohexanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclohexanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(4S,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(5R,6R,9R)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O4 (417.26274300000006)
N-[(5S,6S,9R)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O4 (417.26274300000006)
N-[(5R,6S,9R)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O4 (417.26274300000006)
N-cyclohexyl-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-cyclohexyl-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-cyclohexyl-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
2-(dimethylamino)-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide
2-(dimethylamino)-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide
2-(dimethylamino)-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(1S,3R,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
C23H35N3O4 (417.26274300000006)
2-[(1S,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
C23H35N3O4 (417.26274300000006)
2-[(1S,3S,4aS,9aR)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1S,3R,4aS,9aR)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1S,3R,4aR,9aS)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
4-[4-[(1S,5R)-6-(cyclohexylmethyl)-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]-N,N-dimethylbenzamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclohexanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclohexanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclohexanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclohexanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclohexanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(4S,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(4S,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(4S,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(4R,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
C23H35N3O4 (417.26274300000006)
N-[(5S,6S,9S)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O4 (417.26274300000006)
N-[(5R,6R,9S)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O4 (417.26274300000006)
N-[(5R,6S,9S)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O4 (417.26274300000006)
N-[(5S,6R,9S)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C23H35N3O4 (417.26274300000006)
N-cyclohexyl-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-cyclohexyl-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-cyclohexyl-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-cyclohexyl-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-cyclohexyl-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[(4-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
2-(dimethylamino)-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide
2-(dimethylamino)-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide
2-(dimethylamino)-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide
2-(dimethylamino)-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide
2-(dimethylamino)-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(1R,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
C23H35N3O4 (417.26274300000006)
2-[(1R,3S,4aR,9aS)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1R,3R,4aS,9aR)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1S,3S,4aR,9aS)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1R,3S,4aS,9aR)-6-[[(cyclopentylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
4-[3-(3-methyl-1,3-benzothiazol-2(3H)-ylidene)prop-1-en-1-yl]-1-[3-(trimethylammonio)propyl]quinolinium
C26H31N3S+2 (417.22385660000003)
(3R)-16-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyhexadecanoate
(3R,15R)-15-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyhexadecanoate
3-Hydroxy-2-[[3-(3-hydroxy-6-methylheptanoyl)oxy-8-methylnonanoyl]amino]propanoic acid
4-(2-Octanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Butanoyloxy-2-heptanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Acetyloxy-2-nonanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(2-Hexanoyloxy-3-pentanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
(4R,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid
(2r)-n-{[(2r,3r,4s,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5,5-dimethyloxan-2-yl]methyl}-2-hydroxy-2-[(2r,5r,6r)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]ethanimidic acid
(6e)-2-amino-3,4,5-trihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid
n-({[(1s,2r,3r,4s,6s)-4-amino-3-{[(2r,3r,6s)-3-amino-6-[(methylamino)methyl]oxan-2-yl]oxy}-2-hydroxy-6-methoxycyclohexyl](methyl)carbamoyl}methyl)carboximidic acid
C18H35N5O6 (417.25872100000004)
(1r,4s,6r,7s,11r,12r,15s,16s,17s)-6,7,19-trihydroxy-10,14,15-trimethyl-17-(2-methylpropyl)-2-oxa-18-azatetracyclo[10.7.0.0¹,¹⁶.0⁴,¹¹]nonadeca-9,13,18-trien-3-one
C24H35NO5 (417.25151000000005)
(2r)-2,3-dihydroxypropoxy(2-[(1r,3r,7s,8r,9r)-9-isopropyl-1-methyl-2-methylidene-5-azatricyclo[5.4.0.0³,⁸]undecan-5-yl]ethoxy)phosphinic acid
C20H36NO6P (417.22801260000006)
(1s,3e,10s)-3,17,17-trimethyl-7-methylidene-15-(2-phenylethyl)-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16)-diene-5,14-dione
(2s,3r,5r,6s,7r,10s,11s)-3,6,7,15-tetramethyl-18-azahexacyclo[12.11.0.0²,¹¹.0⁶,¹¹.0¹⁷,²⁵.0¹⁹,²⁴]pentacosa-1(14),15,17(25),19(24),20,22-hexaene-5,10-diol
methyl 6-hydroxy-6-isopropyl-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C24H35NO5 (417.25151000000005)
(1r,3r,5r,6r,7r,10z,15s,16r)-6,7,19-trihydroxy-10,14,15-trimethyl-17-(2-methylpropyl)-4-oxa-18-azatetracyclo[10.7.0.0¹,¹⁶.0³,⁵]nonadeca-10,13,18-trien-2-one
C24H35NO5 (417.25151000000005)
(1r,2r,4s,5s,7s,8s,12s,13s,18s,20r,21s)-4-hydroxy-4,12-dimethyl-14,19-dioxa-17-azaheptacyclo[10.7.2.2²,⁵.0²,⁷.0⁸,¹⁸.0⁸,²¹.0¹³,¹⁷]tricosan-20-yl acetate
C24H35NO5 (417.25151000000005)
3,6,7,15-tetramethyl-18-azahexacyclo[12.11.0.0²,¹¹.0⁶,¹¹.0¹⁷,²⁵.0¹⁹,²⁴]pentacosa-1(14),15,17(25),19(24),20,22-hexaene-5,10-diol
(5s,6r,10as,13s,13as,14s,16ar)-5,6,16-trihydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-5h,6h,7h,8h,10ah,13h,13ah,14h-oxacyclododeca[2,3-d]isoindol-2-one
C24H35NO5 (417.25151000000005)
(5r,6s,10as,13s,13as,14s,16ar)-5,6,16-trihydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-5h,6h,7h,8h,10ah,13h,13ah,14h-oxacyclododeca[3,2-d]isoindol-2-one
C24H35NO5 (417.25151000000005)